87 related articles for article (PubMed ID: 24051218)
1. Molecular pathogenesis in non-Hodgkin lymphoma: implications for therapy.
Vose JM
Transfus Apher Sci; 2013 Oct; 49(2):155-6. PubMed ID: 24051218
[TBL] [Abstract][Full Text] [Related]
2. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
Rasmussen PK
Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
[TBL] [Abstract][Full Text] [Related]
3. Molecular Classification of Diffuse Large B-cell Lymphoma: What Is Clinically Relevant?
Sujobert P; Salles G; Bachy E
Hematol Oncol Clin North Am; 2016 Dec; 30(6):1163-1177. PubMed ID: 27888873
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological features of aggressive B-cell lymphomas including B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell and Burkitt lymphomas: a study of 44 patients from Argentina.
Bürgesser MV; Gualco G; Diller A; Natkunam Y; Bacchi CE
Ann Diagn Pathol; 2013 Jun; 17(3):250-5. PubMed ID: 23246412
[TBL] [Abstract][Full Text] [Related]
5. Genomic profiling using array comparative genomic hybridization define distinct subtypes of diffuse large B-cell lymphoma: a review of the literature.
Tirado CA; Chen W; García R; Kohlman KA; Rao N
J Hematol Oncol; 2012 Sep; 5():54. PubMed ID: 22967872
[TBL] [Abstract][Full Text] [Related]
6. MicroRNAs in diffuse large B-cell lymphoma: implications for pathogenesis, diagnosis, prognosis and therapy.
Troppan K; Wenzl K; Deutsch A; Ling H; Neumeister P; Pichler M
Anticancer Res; 2014 Feb; 34(2):557-64. PubMed ID: 24510984
[TBL] [Abstract][Full Text] [Related]
7. Primary cutaneous diffuse large B-cell lymphoma (PCDLBCL), leg-type and other: an update on morphology and treatment.
Paulli M; Lucioni M; Maffi A; Croci GA; Nicola M; Berti E
G Ital Dermatol Venereol; 2012 Dec; 147(6):589-602. PubMed ID: 23149705
[TBL] [Abstract][Full Text] [Related]
8. FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1.
Hoeller S; Schneider A; Haralambieva E; Dirnhofer S; Tzankov A
Histopathology; 2010 Jul; 57(1):73-80. PubMed ID: 20579129
[TBL] [Abstract][Full Text] [Related]
9. Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma: Genetic Classification and Its Implications for Prognosis and Treatment.
Crombie JL; Armand P
Hematol Oncol Clin North Am; 2019 Aug; 33(4):575-585. PubMed ID: 31229155
[TBL] [Abstract][Full Text] [Related]
10. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
[TBL] [Abstract][Full Text] [Related]
11. Cellular (FLICE) like inhibitory protein (cFLIP) expression in diffuse large B-cell lymphoma identifies a poor prognostic subset, but fails to predict the molecular subtype.
Harris J; Ibrahim H; Amen F; Karadimitris A; Naresh KN; Macdonald DH
Hematol Oncol; 2012 Mar; 30(1):8-12. PubMed ID: 21638304
[TBL] [Abstract][Full Text] [Related]
12. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.
Choi JW; Kim Y; Lee JH; Kim YS
Hum Pathol; 2013 Jul; 44(7):1375-81. PubMed ID: 23380077
[TBL] [Abstract][Full Text] [Related]
13. Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome.
Larouche JF; Berger F; Chassagne-Clément C; Ffrench M; Callet-Bauchu E; Sebban C; Ghesquières H; Broussais-Guillaumot F; Salles G; Coiffier B
J Clin Oncol; 2010 Apr; 28(12):2094-100. PubMed ID: 20308668
[TBL] [Abstract][Full Text] [Related]
14. [Cytogenetic study on 155 cases of non-Hodgkin' s lymphoma].
Wang XQ;
Zhonghua Xue Ye Xue Za Zhi; 2006 Oct; 27(10):656-60. PubMed ID: 17343195
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of CD44v6 in diffuse large B-cell lymphoma.
Inagaki H; Banno S; Wakita A; Ueda R; Eimoto T
Mod Pathol; 1999 May; 12(5):546-52. PubMed ID: 10349995
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis.
Ghesquières H; Berger F; Felman P; Callet-Bauchu E; Bryon PA; Traverse-Glehen A; Thieblemont C; Baseggio L; Michallet AS; Coiffier B; Salles G
J Clin Oncol; 2006 Nov; 24(33):5234-41. PubMed ID: 17043351
[TBL] [Abstract][Full Text] [Related]
17. High frequency and strong prognostic relevance of O6-methylguanine DNA methyltransferase silencing in diffuse large B-cell lymphomas from the Middle East.
Al-Kuraya K; Narayanappa R; Siraj AK; Al-Dayel F; Ezzat A; El Solh H; Al-Jommah N; Sauter G; Simon R
Hum Pathol; 2006 Jun; 37(6):742-8. PubMed ID: 16733216
[TBL] [Abstract][Full Text] [Related]
18. Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma.
Rodig SJ; Savage KJ; LaCasce AS; Weng AP; Harris NL; Shipp MA; Hsi ED; Gascoyne RD; Kutok JL
Am J Surg Pathol; 2007 Jan; 31(1):106-12. PubMed ID: 17197926
[TBL] [Abstract][Full Text] [Related]
19. Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities.
De Paepe P; De Wolf-Peeters C
Leukemia; 2007 Jan; 21(1):37-43. PubMed ID: 17039226
[TBL] [Abstract][Full Text] [Related]
20. Secondary CD5+ diffuse large B-cell lymphoma not associated with transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (Richter syndrome).
Maeshima AM; Taniguchi H; Nomoto J; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Matsuno Y
Am J Clin Pathol; 2009 Mar; 131(3):339-46. PubMed ID: 19228640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
